Keyword: Teva Pharmaceutical
Analysts may have their concerns about Teva’s growth prospects, but Warren Buffett apparently still likes what he sees at the Israeli drugmaker.
Kickbacks whistleblowers reached their "put up or shut up" moment for producing solid evidence—and didn't, Teva says.
Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.
A reinspection of Celltrion's South Korea plant resulted in another Form 483, but not a serious one.
Mylan may have cut the list price on its Copaxone copy, but the Israeli drugmaker says it’s still on track to rake in significant 2018 sales.
Teva's selected an address in Parsippany, but it still has plenty of work to do before it can move into its new U.S. headquarters.
Thanks to Mylan’s price cut on generic Copaxone, Teva’s going to have to take the price on its branded product down. And it may be wise to start now.
Certain valsartan drugs made by Teva, Major Pharmaceuticals and Solco Healthcare—the U.S. subsidiary of the API supplier in question—are being recalled.
Mylan has slashed its list price on generic Copaxone, and the move has industry watchers scratching their heads.
Looks like New Jersey’s $40 million plan to lure Teva’s headquarters from Pennsylvania worked.